financetom
Business
financetom
/
Business
/
Hudbay Minerals Receives New Ingerbelle Expansion Permits for Copper Mountain
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hudbay Minerals Receives New Ingerbelle Expansion Permits for Copper Mountain
Mar 11, 2026 4:59 AM

01:04 PM EST, 02/20/2026 (MT Newswires) -- Hudbay Minerals ( HBM ) on Friday said it received key permit amendments for the New Ingerbelle expansion project at its Copper Mountain mine located in British Columbia.

The company said it received the amended Mines Act and Environmental Management Act permits through the coordinated authorizations process managed by the British Columbia Major Mines Office.

In a statement the company noted that this enhances the copper and gold production profile at Copper Mountain, secures a longer mine life, protects more than 800 jobs and ensures continued economic benefits at the local, regional and federal levels.

"The New Ingerbelle permit ensures that we'll be able to advance this major project while extending our partnership with local communities to facilitate additional growth investments at Copper Mountain and further adds to our 99 years of successful operations in Canada," said chief executive Peter Kukielski. "Our efforts to optimize Copper Mountain, combined with the development of New Ingerbelle, will unlock significant long-term value for all of our stakeholders."

The company's shares were last seen down $0.50 to $33.36 on the Toronto Stock Exchange.

Price: 33.30, Change: -0.56, Percent Change: -1.65

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Essex Property Trust Acquires JV Partner's Interest In Four Communities Comprising 1,480 Apartment Homes
BRIEF-Essex Property Trust Acquires JV Partner's Interest In Four Communities Comprising 1,480 Apartment Homes
Mar 25, 2024
March 25 (Reuters) - Essex Property Trust Inc ( ESS ): * ESSEX PROPERTY TRUST ACQUIRES JOINT VENTURE PARTNER'S INTEREST IN FOUR COMMUNITIES COMPRISING 1,480 APARTMENT HOMES * ESSEX PROPERTY TRUST INC ( ESS ): ACQUIRED JV PARTNER'S 49.9% INTEREST IN BEXAEW PORTFOLIO FOR A TOTAL PURCHASE PRICE OF $505 MILLION ON A GROSS BASIS * ESSEX PROPERTY TRUST INC...
Lucid Group Secures $1 Billion from Ayar Third Investment to Help Fund Future Operations; Share Climb
Lucid Group Secures $1 Billion from Ayar Third Investment to Help Fund Future Operations; Share Climb
Mar 25, 2024
10:05 AM EDT, 03/25/2024 (MT Newswires) -- Lucid Group ( LCID ) rallied early Monday after saying majority owner Ayar Third Investment Co. will buy $1 billion of a new series of its convertible preferred stock through a private placement with the electric vehicle powertrain company, subject to customary closing conditions. Specific terms of the convertible preferred stock sale were...
Cryo-Cell International to Spin Off Celle Unit, Explore Strategic Alternatives; Shares Jump
Cryo-Cell International to Spin Off Celle Unit, Explore Strategic Alternatives; Shares Jump
Mar 25, 2024
09:56 AM EDT, 03/25/2024 (MT Newswires) -- Cryo-Cell International ( CCEL ) said Monday that its board has approved the spinoff of its Celle unit to the company's shareholders and the move to look into strategic alternatives for Cryo-Cell ( CCEL ) post-spinoff, including a possible sale or merger. The spinoff of the newly created Celle unit is expected to...
Regeneron Shares Down After FDA Letter Questioning Application for Potential Lymphoma Treatment
Regeneron Shares Down After FDA Letter Questioning Application for Potential Lymphoma Treatment
Mar 25, 2024
09:52 AM EDT, 03/25/2024 (MT Newswires) -- Regeneron Pharmaceuticals' ( REGN ) shares were down nearly 1 percent in early trading Monday after it received negative feedback from the Food and Drug Administration regarding its Biologics License Application for odronextamab, a potential treatment for relapsed or refractory forms of both follicular lymphoma and diffuse large B-cell lymphoma. The company said...
Copyright 2023-2026 - www.financetom.com All Rights Reserved